Ulla Holm Hansen

Ulla Holm Hansen has a diverse work experience spanning over several sectors. Ulla Holm began their career in the healthcare field, working as a Registered Nurse in various departments including acute cardiology, orthopedics, oncology, and hematology. In 2000, they transitioned to the role of Trainee Anaesthetics Nurse in the Department of Anaesthesia.

In 2000, Ulla entered the clinical research field as a Clinical Research Associate at Medicon A/S. Ulla Holm then joined Novartis A/S in 2005, where they served as a Senior Clinical Research Associate and later as a Project Manager in the areas of ophthalmology, respiration, and neuroscience.

In 2010, Ulla joined Symphogen as a Lead Clinical Research Associate in Immunotherapy. Throughout their tenure at Symphogen, Ulla held various positions including Clinical Trial Manager, Senior Clinical Trial Manager for Oncology in the USA, and eventually became the Director of Clinical Operations. Ulla Holm continued in this role until 2021 when Symphogen merged with Servier, and they assumed the position of Director of IND & Phase I at Symphogen, now a Servier company.

Most recently, in 2023, Ulla joined Alligator Bioscience AB as the VP of Clinical Operations.

Ulla Holm Hansen obtained a Bachelor's Degree in Registered Nursing/Registered Nurse from the University College Lillebælt, where they studied from 1989 to 1993. Ulla Holm later pursued a Master's Degree in Industrial Drug Development from the University of Copenhagen, from 2015 to 2022.